Art. -Nr.: HY-14664A

Fluvastatin sodium

(Synonyms: XU 62-320)

20 Cited Publications

Kundenbewertung

Based on 20 publication(s) in Google Scholar

Fluvastatin sodium (XU 62320) is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC₅₀ of 8 nM. Fluvastatin sodium protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.94%
CAS. Nr.: 93957-55-2
Formel: C₂₄H₂₅FNNaO₄
Molecular Weight:433.45

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Fluvastatin sodium Chemical Structure

CAS. Nr.: 93957-55-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (20)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 8 nM (HMG-CoA reductase)^[1]

In Vitro

Fluvastatin sodium (XU 62320) is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR), the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Human hepatocellular carcinoma cell (HCC) studies indicate that Fluvastatin induces G2/M phase arrest. In the presence of Fluvastatin (XU 62320), HCC cells show a decrease of Bcl-2 and procaspase-9 expression, and an increase in Bax, cleaved caspase-3, and cytochrome c. Fluvastatin (XU 62320) is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 93957-55-2
Appearance Solid
Molecular Weight 433.45
Formel C₂₄H₂₅FNNaO₄
Color Light yellow to yellow
SMILES

O=C(O[Na])C[C@H](O)C[C@H](O)/C=C/C(N1C(C)C)=C(C2=CC=C(F)C=C2)C3=C1C=CC=C3
Synonyms

XU 62-320
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Publications (20)

All RT-PCRCell Proliferation/Viability AssayIn Vivo Efficacy StudyIHCFlow Cytometry

Sort by:

Journal Impact Factor

Cell Rep Med

A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [Abstract]

2024 May 29:101592. PMID: 38843841

Fluvastatin sodium purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 May 29:101592. [Abstract]

HFD C57BL/6 mice intravenously injected with 1 × 10⁶ Cd36^NC or Cd36^KO C1498 cells were treated with or without reagents (fluvastatin, 40 mg/kg, 5 times/week, intragastric).

Fluvastatin sodium purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 May 29:101592. [Abstract]

Tumors from 3 recipients were dissected for immunohistochemistry staining with anti-human CD3 antibody treated with fluvastatin (40 mg/kg, 5 times/week, i.g.) for 2 weeks.

Fluvastatin sodium purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 May 29:101592. [Abstract]

NOG mice intravenously implanted with 5 × 10⁶ BMMCs from patients with AML were treated with or without fluvastatin (40 mg/kg, 5 times/week, i.g.) for 2 weeks starting 7 days after implantation. 3 days after the last treatment, percentages of human AML cells and human T cells in BM were tested.
Chem Eng J

1 January 2023, 138972.
Pharmacol Res

Organic anion-transporting polypeptide 2B1 knockout and humanized mice; insights into the handling of bilirubin and drugs. [Abstract]

2023 Apr:190:106724. PMID: 36907287
Phytother Res

Toosendanin Induces Cell Cycle Arrest and Apoptosis to Suppress Diffuse Large B-Cell Lymphoma Growth by Inhibiting PI3Kα/β and PLK1 Signaling. [Abstract]

2025 May;39(5):1930-1945. PMID: 39949030
Cell Prolif

Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. [Abstract]

2021 Jan;54(1):e12953. PMID: 33211371
PLoS Biol

FOXA3 regulates cholesterol metabolism to compensate for low uptake during the progression of lung adenocarcinoma. [Abstract]

2024 May 28;22(5):e3002621. PMID: 38805565

Fluvastatin sodium purchased from MedChemExpress. Usage Cited in: PLoS Biol.2024 May 28;22(5):e3002621. [Abstract]

The 7-DHC, cholesterol levels, and qRT-PCR analyses of metastatic-related genes of A549 cells cultured in LPDS medium treated with 5 μg/mL cholesterol with or without 10 μM fluvastatin for 24 h.

Fluvastatin sodium purchased from MedChemExpress. Usage Cited in: PLoS Biol.2024 May 28;22(5):e3002621. [Abstract]

Cell viability of foxa3^hi PDO treated with 10 μM Magnolol, 10 μM Fluvastatin, or 10 μM Cisplatin by ATP assay.
Front Bioeng Biotechnol

Application of 3D Hepatic Plate-Like Liver Model for Statin-Induced Hepatotoxicity Evaluation. [Abstract]

2022 Mar 17;10:826093. PMID: 35372314
Front Cell Dev Biol

Construction of Escherichia coli Whole-Cell Biosensors for Statin Efficacy and Production Test. [Abstract]

2020 May 28;8:404. PMID: 32671060
ACS Omega

Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]

2025 Oct 29;10(44):52562-52575. PMID: 41244417
Mol Med Rep

Protection against monocrotaline-induced pulmonary arterial hypertension and caveolin-1 downregulation by fluvastatin in rats. [Abstract]

2018 Mar;17(3):3944-3950. PMID: 29286128
FASEB J

Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin-1-Mediated PI3K/AKT Signaling Pathway in Cisplatin-Resistant Cervical Cancer Cells. [Abstract]

2026 May 15;40(9):e71873. PMID: 42087353
Proteomics

A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells. [Abstract]

2023 Aug;23(16):e2300041. PMID: 37140101
Pathogens

Proteomic Discovery of VEEV E2-Host Partner Interactions Identifies GRP78 Inhibitor HA15 as a Potential Therapeutic for Alphavirus Infections. [Abstract]

2021 Mar 2;10(3):283. PMID: 33801554
Front Oncol

Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor. [Abstract]

2021 May 10:11:595285. PMID: 34041015
FEBS Open Bio

Statins induce monocytic differentiation in acute myeloid leukemia cells through the KLF4/DPYSL2A axis. [Abstract]

2025 Aug 8. PMID: 40781787
Biochem Biophys Res Commun

Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. [Abstract]

2020 Feb 19;522(4):862-868. PMID: 31806372
SSRN

2025 Dec 2.
SSRN

2025 Jul 7.
bioRxiv

2024 October 04.
Biomed Pharmacother

Interplay of OATP1A/1B/2B1 uptake transporters and ABCB1 and ABCG2 efflux transporters in the handling of bilirubin and drugs. [Abstract]

2024 Jun:175:116644. PMID: 38692057

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 50 mg/mL (115.35 mM; Need ultrasonic)

DMSO : 50 mg/mL (115.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3071 mL

11.5354 mL

23.0707 mL

5 mM

0.4614 mL

2.3071 mL

4.6141 mL

10 mM

0.2307 mL

1.1535 mL

2.3071 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Makabe S, et al. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway. Atherosclerosis. 2010 Dec;213(2):377-84. [Content Brief]

[2]. Wu Zhang, et al. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol. 2010 Dec;48(12):1167-74. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.3071 mL	11.5354 mL	23.0707 mL	57.6768 mL
	5 mM	0.4614 mL	2.3071 mL	4.6141 mL	11.5354 mL
	10 mM	0.2307 mL	1.1535 mL	2.3071 mL	5.7677 mL
	15 mM	0.1538 mL	0.7690 mL	1.5380 mL	3.8451 mL
	20 mM	0.1154 mL	0.5768 mL	1.1535 mL	2.8838 mL
	25 mM	0.0923 mL	0.4614 mL	0.9228 mL	2.3071 mL
	30 mM	0.0769 mL	0.3845 mL	0.7690 mL	1.9226 mL
	40 mM	0.0577 mL	0.2884 mL	0.5768 mL	1.4419 mL
	50 mM	0.0461 mL	0.2307 mL	0.4614 mL	1.1535 mL
	60 mM	0.0385 mL	0.1923 mL	0.3845 mL	0.9613 mL
	80 mM	0.0288 mL	0.1442 mL	0.2884 mL	0.7210 mL
	100 mM	0.0231 mL	0.1154 mL	0.2307 mL	0.5768 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Fluvastatin sodium

20 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Fluvastatin sodium

Anti-Infection Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Lipid Metabolism Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Fluvastatin sodium

Biologische Aktivität

Chemical Information

Publications (20)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Fluvastatin sodium Related Classifications

HY-14664A Related Classifications